In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus Δσ
Open Access
- 11 January 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (3) , 755-762
- https://doi.org/10.1002/hep.24171
Abstract
Control of hepatitis C virus (HCV) infection remains a huge challenge of global medical importance. Using a variety of in vitro approaches, neutralizing antibodies (nAbs) have been identified in patients with acute and chronic hepatitis C. The exact role these nAbs play in the resolution of acute HCV infection still remains elusive. We have previously shown that purified polyclonal antibodies isolated from plasma obtained in 2003 from a chronic HCV patient (Patient H) can protect human liver chimeric mice from a subsequent challenge with the autologous HCV strain isolated from Patient H in 1977 (H77). In this study we investigated whether polyclonal antibodies isolated from Patient H in 2006 (H06), which display high cross-genotype neutralizing activity in both the HCV pseudoparticle (HCVpp) and HCV cell culture (HCVcc) systems, were also able to prevent HCV infection of different genotypes (gt) in vivo. Following passive immunization with H06-antibodies, chimeric mice were challenged with the consensus strains H77C (gt1a), ED43 (gt4a), or HK6a (gt6a). In accordance with previous results, H06-antibodies prevented infection of chimeric mice with the autologous virus. However, the outcome of a homologous challenge is highly influenced by the amount of challenge virus injected. Depending on the viral genotype used, H06-antibodies were able to protect up to 50% of chimeric mice from a heterologous challenge. Animals in which the antibody pretreatment failed displayed a clear delay in the kinetics of viral infection. Sequence analysis of the recovered viruses did not suggest antibody-induced viral escape. Conclusion: Polyclonal anti-HCV antibodies isolated from a chronic HCV patient can protect against an in vivo challenge with different HCV genotypes. However, the in vivo protective efficacy of cross-genotype neutralizing antibodies was less than predicted by cell culture experiments. (Hepatology 2011)Keywords
This publication has 32 references indexed in Scilit:
- Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationThe Journal of Experimental Medicine, 2010
- Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and In Vivo Pathogenesis StudiesJournal of Virology, 2010
- Challenge Pools of Hepatitis C Virus Genotypes 1–6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liver–Chimeric Mouse ModelsThe Journal of Infectious Diseases, 2010
- Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C VirusJournal of Virology, 2009
- uPA+/+-SCID Mouse with Humanized Liver as a Model for In Vivo Metabolism of Exogenous Steroids: Methandienone as a Case StudyClinical Chemistry, 2009
- Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activityProceedings of the National Academy of Sciences, 2009
- Development of hepatitis C virus vaccines: challenges and progressExpert Review of Vaccines, 2009
- Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs # †Hepatology, 2009
- Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein ComplexesThe Journal of Experimental Medicine, 2003
- Five-Year Follow-up of Patients with Primary Antibody Deficiencies Following an Outbreak of Acute Hepatitis CClinical Immunology, 2001